Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Anheuser-Busch Inbev SA (BUD) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance

Anheuser-Busch Inbev SATrade
Citius Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Anheuser-Busch Inbev SA vs Citius Pharmaceuticals Inc — how do they compare? Anheuser-Busch Inbev SA trades at $79.34 (market cap $159.01B), while Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M). The key difference: Anheuser-Busch Inbev SA is far larger — about 7946.5× Citius Pharmaceuticals Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

BUDCTXR
Market Cap
$159.01B$20.01M
Sector
Consumer StaplesHealth
52-Week High
$86.48$1.82
52-Week Low
$57.93$0.48
Enterprise Value
$223.42B$16.23M
Dividend Yield
1.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Anheuser-Busch Inbev SA

BUD trades at $79.3, down 4.56% on the day, with a bearish technical signal from moving averages and oscillators. Fundamentally, the company reported Q2 2026 EPS of $1.21, beating estimates, and maintains strong cash flow with $14.88B from operations in 2025. Revenue for 2025 was $59.32B, with net income margin improving to 11.52%. Recent news includes mixed institutional activity and Q2 earnings coverage highlighting volume growth and premium brand strength.

The outlook is supported by analyst consensus with a $90.17 price target and 57.78% buy ratings, but risks include recent shareholder share sales and competitive pressures. Earnings growth and deleveraging trends provide upside, while technical weakness near support at $79 requires monitoring for stability.

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Anheuser-Busch Inbev SA

Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.

Read more on BUD

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR